Detailed Review of Efsubaglutide Alfa's Drug Actions and Effects

Efsubaglutide alfa has a terminal half-life of approximately 182-215 hours.

• Prolonged exposure and low steady-state fluctuation are observed with efsubaglutide alfa.
• Steady-state trough concentration is linked to glycaemic response, while average and peak concentrations relate to weight response and gastrointestinal tolerability.
• Class-consistent improvements in glycaemic control and body weight have been noted, primarily in Chinese populations.
• Gastrointestinal adverse events are the main limitation to tolerability reported.
• Exploratory findings on dosing every 2 weeks and glycaemic durability after discontinuation warrant further investigation.
• Current evidence primarily serves as a synthesis of clinical pharmacology rather than a comparative claim due to the lack of large, diverse datasets.

Simplified